Table 2: Comparing main meta-analysis in terms of overall survival and morbidity.

Authors Year publishedType of studyStage of GCNumber of patientsType of protocolOverall survivalPeritoneal recurrence Mortality and morbidity

Yan et al. [11]2007Meta-analysis
(13 RCTs)
Stage I–IV1648Surgery + HIPEC/HIPEC + EPIC/NIIC versus surgery alone ± systemic chemotherapy HR = 0.601
HR = 0.452
HR = 0.673
RR = 0.84
RR = 0.51
RR = 1.00
RR = 1.43
RR = 1.01/1.81/0.76/2.37/4.33#
Jin-Yu et al. [12]2012Meta-analysis
(15 RCTs)
N/A1713HIPEC versus HIPEC + PIC versus NIICHR = 0.60
HR = 0.47
HR = 0.70
OR = 0.69 OR = 2.29
OR = 1.04/2.60/1.61/0.39/5.74/3.67/3.57$
Sun et al. [13]2012Meta-analysis
(10 RCTs)
Stage II-III1062HIPEC* versus surgery MMC RR = 0.75
5-FU RR = 0.69
RR = 0.45N/A for Mortality
RR = 1.68/0.52/1.38/0.79/1.47£

HR: hazard ratio; RR: risk ratio; OR: odds ratio; MMC: mitomycin C; 5-FU: 5-fluorouracil; HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIC: NIIC: normothermic intraoperative intraperitoneal chemotherapy; RCS: retrospective case series; PCS: prospective case series; N/A: not available; PC: peritoneal carcinomatosis.
1,2,3HIPEC, HIPEC + EPIC, and NIIC, respectively.
No differences in morbidity between HIPEC and NIIC groups and the respective control arms.
#Morbidity of anastomotic leak, bowel fistula, pancreatic fistula, intra-abdominal abscess, and neutropenia, respectively.
*Data calculated with risk ratio (RR) and divided in two subgroups for analysis: mitomycin C subgroup RR = 0.75, 5-Fluorouracil RR = 0.69 versus control group RR = 0.45.
£Morbidity of bone marrow suppression, anastomotic leak, bowel fistula, adhesive ileus, and liver disfunction, respectively.
$Morbidity of anastomotic leak, ileus, bowel perforation, pancreatic fistula, marrow depression, fever, and intra-abdominal abscess, respectively.